PCRX — PharmaCorp Rx Income Statement
0.000.00%
Last trade - 00:00- CA$55.72m
- CA$44.00m
- CA$5.79m
- 50
- 19
- 41
- 29
Annual income statement for PharmaCorp Rx, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 0 | 5.79 |
| Cost of Revenue | ||||
| Gross Profit | — | — | — | 2.18 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Total Operating Expenses | 0.027 | 0.563 | 0.578 | 7.4 |
| Operating Profit | -0.027 | -0.563 | -0.578 | -1.6 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -0.026 | -0.517 | -0.47 | -1.16 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.026 | -0.517 | -0.47 | -1.05 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.026 | -0.517 | -0.47 | -1.01 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.026 | -0.517 | -0.47 | -1.01 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.001 | -0.016 | -0.012 | -0.012 |
| Dividends per Share |